SFFS
IBRX icon

Stonehage Fleming Financial Services’s ImmunityBio IBRX Stock Holding History

Stonehage Fleming Financial Services’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-85,000
Closed -$144K – 258
2023
Q3 		$144K Buy
+85,000
New +$171K 0.01% 164
2022
Q3 		– Sell
-60,000
Closed -$223K – 218
2022
Q2 		$223K Hold
60,000
– – 0.01% 141
2022
Q1 		$336K Buy
+60,000
New +$368K 0.01% 132

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Stonehage Fleming Financial Services's IBRX Position: Q4 2023 in Review

Stonehage Fleming Financial Services sold out of ImmunityBio (IBRX) in Q4 2023, closing a stake of 85,000 shares — an estimated $144K sold.

Stonehage Fleming Financial Services first reported a position in IBRX in Q1 2022 and held it in 3 quarters. The position peaked at $336K in Q1 2022. 147 funds tracked by Wall St. Rank hold IBRX as of Q4 2023.

  • Stonehage Fleming Financial Services reported no remaining ImmunityBio position as of Q4 2023 after selling out during the quarter.
  • Stonehage Fleming Financial Services sold 85,000 ImmunityBio shares in Q4 2023, an estimated $144K.
  • Stonehage Fleming Financial Services first reported a position in ImmunityBio in Q1 2022 and held it in 3 quarters.
  • Stonehage Fleming Financial Services's ImmunityBio position peaked at $336K in Q1 2022.
  • 147 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2023.

Based on Stonehage Fleming Financial Services's 13F filing for Q4 2023, filed 14 Feb 2024.